Author: Brian Bamberger

How Pharmaceutical Companies Could be Affected by the AMA’s Prior Authorization and Utilization Management Reform Proposal

Prior authorization (PA) for medications, devices and services is viewed as a valuable utilization management tool by payers but is a long-standing pain point for providers, pharmacists and the pharmaceutical …

NCPDP Action Group Focused on Biologics and Biosimilars

By Brian Bamberger, Practice Lead, Life Sciences Biologics and biosimilars are starting to burst into the American market. Biosimilars are expected to quickly become mainstream in the near future because …